Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AQST vs MNOV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MNOV Captures Overall Composite Edge (50.2 HOLD vs 62.9 BUY), While AQST Leads 3–2 on Growth & Valuation Pillars
MNOV Overall Winner
6-Pillar Tally: AQST 3 – 2 MNOV (1 Tie)
Matrix Metrics: AQST 5 – 5 MNOV
As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (50.2/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 5–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. AQST trades at $3.46 (N/M Forward P/E, -114.1% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin).
- Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. MNOV 50.2/100 HOLD), MNOV captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1232.2% vs. -114.1% operating margin) and revenue trajectory (+12.4% vs. -41.0% YoY).
- Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AQST vs MNOV
AQST
Aquestive Therapeutics, Inc. Common Stock
$3.46
-6.61% 1D
Market Cap
$465.7M
TTM Revenue
$49M
Forward P/E
N/M
Beta / 30D Vol
0.89β · 56% Vol
Unified Composite Score
62.9
BUY
Tech 54.0
Fund 68.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
MNOV
Head-to-Head Winner
Medicinova, Inc.
$1.31
+3.15% 1D
Market Cap
$65.1M
TTM Revenue
$935,717
Forward P/E
8.5x
Beta / 30D Vol
0.59β · 38% Vol
Unified Composite Score
50.2
HOLD
Tech 47.0
Fund 46.0
Flow 63.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (AQST 3 – 2 MNOV)
1. Valuation Multiples
MNOV
Forward P/E
N/M
8.5x
Trailing P/E
N/M
8.5x
PEG Ratio
N/M
N/M
EV / Revenue
8.9x
42.5x
2. Growth & Scale
AQST
Revenue Growth (YoY)
-41.0%
+12.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$49M
$935,717
Market Cap
$465.7M
$65.1M
3. Profitability & Quality
AQST
Gross Margin
65.3%
42.2%
Operating Margin
-114.1%
-1232.2%
Net Profit Margin
-162.3%
0.0%
Return on Equity (ROE)
0.0%
-24.8%
4. Balance Sheet & Cash Flow
MNOV
Cash Generation (TTM)
-$41M
-$9.1M
Cash Flow Margin
-83.3%
N/A
Net Cash / Leverage
$32M Net Cash
$25M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AQST
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
87.9% (64th %ile)
140.1% (50th %ile)
Put/Call OI Skew
0.98x (Balanced)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AQST (5) vs MNOV (5)| Institutional Metric | AQST | MNOV | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $465.7M | $65.1M | AQST | |
| Trailing P/E Ratio | N/M | 8.5x | MNOV | |
| Forward P/E Ratio | N/M | 8.5x | MNOV | |
| Revenue Growth (YoY) | -41.0% | +12.4% | MNOV | |
| Operating Margin (TTM) | -114.1% | -1232.2% | AQST | |
| Net Profit Margin | -162.3% | 0.0% | MNOV | |
| Return on Equity (ROE) | 0.0% | -24.8% | AQST | |
| 52-Week Range Position | 14% ($3–$7) | 3% ($1–$4) | AQST | |
| Beta / 30D Volatility | 0.89β · 56% Vol | 0.59β · 38% Vol | MNOV | |
| Unified Institutional Score | 62.9 / 100 (BUY) | 50.2 / 100 (HOLD) | AQST | |
| Trailing 12M Revenue (USD) | $49M | $935,717 | Scale | |
| Gross Profit Margin (TTM) | 65.3% | 42.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 8.9x EV/Rev | N/M PEG · 42.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$41M ($32M Net Cash) | -$9.1M ($25M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MNOV +9.13 pp
3M Horizon
MNOV +13.54 pp
6M Horizon
MNOV +9.59 pp
1Y Horizon
MNOV +32.26 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AQST Revenue | MNOV Revenue | AQST Op. Margin | MNOV Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $70M | N/A | -72.6% | N/A | AQST |
| FY2019 | $50M | N/A | -100.1% | N/A | AQST |
| FY2020 | $50M | N/A | -93.6% | N/A | AQST |
| FY2021 | $50M | $0M | -68.2% | -253.0% | AQST |
| FY2022 | $50M | N/A | -88.2% | N/A | AQST |
| FY2023 | $50M | $0M | -29.9% | -990.0% | AQST |
| FY2024 | $60M | N/A | -53.5% | N/A | AQST |
| FY2025 | $40M | $0M | -159.5% | -3242.5% | AQST |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AQST
BREAKDOWN
Current IV
87.9%
IV Percentile
64th %ile
Put/Call OI Skew
0.98x (Balanced)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MNOV
UNCLASSIFIED
Current IV
140.1%
IV Percentile
50th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AQST Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MNOV Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ AQST vs MNOV Key Questions & Quantitative Answers
As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Aquestive Therapeutics, Inc. (AQST) on higher Unified Composite conviction (50.2/100 HOLD vs. 62.9/100 BUY) after splitting the core matrix 5–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while AQST wins 3–2 across the 6-pillar growth and valuation breakdown. AQST trades at $3.46 (N/M Forward P/E, -114.1% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. MNOV 50.2/100 HOLD), MNOV captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1232.2% vs. -114.1% operating margin) and revenue trajectory (+12.4% vs. -41.0% YoY). Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AQST leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AQST cumulative revenue shifted -42.9% while MNOV shifted N/A. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.
MNOV screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus MNOV (-24.8% ROE) capital efficiency.
In options market volatility and institutional positioning, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MNOV vs AQST · Reverse Pair
AQST vs SVRA
· Sector Peer
AQST vs ETON
· Sector Peer
AQST vs XERS
· Sector Peer
MNOV vs ENTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma